Erich Lehner, head of the life science branch at EY Austria, a worldwide leading consultancy firm, provides an insight into the current mandate of EY Austria as well as the services and one stop shop approach they provide for their three main focuses; Big Pharma, small to mid-size biotechs and public institutes. He also discusses the catalysts for future market growth and what makes Austria an attractive investment destination.
As the head of the life sciences branch at EY Austria, could you introduce to our international readers your current activities?
"As a life science community, we need to create a more comfortable environment, including tax incentives for example, to ensure these businesses can focus on R&D rather than financial concerns."
